[Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results]. [electronic resource]
Producer: 20170818Description: 945-50 p. digitalISSN:- 1439-3999
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Bevacizumab -- administration & dosage
- Drug Administration Schedule
- Drug Substitution -- methods
- Drug Therapy, Combination -- methods
- Female
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Prevalence
- Ranibizumab -- administration & dosage
- Receptors, Vascular Endothelial Growth Factor -- administration & dosage
- Recombinant Fusion Proteins -- administration & dosage
- Retrospective Studies
- Risk Factors
- Switzerland -- epidemiology
- Treatment Outcome
- Visual Acuity -- drug effects
- Wet Macular Degeneration -- diagnosis
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.